TZP 102

Drug Profile

TZP 102

Alternative Names: TZP-102

Latest Information Update: 14 Dec 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Tranzyme
  • Developer Ocera Therapeutics
  • Class Macrocyclic compounds; Small molecules
  • Mechanism of Action Ghrelin agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • No development reported Diabetic gastroparesis

Most Recent Events

  • 11 Dec 2017 Ocera Therapeutics has been acquired by Mallinckrodt
  • 04 Sep 2013 No development reported - Phase-II for Diabetic gastroparesis in United Kingdom (PO)
  • 04 Sep 2013 No development reported - Phase-II/III for Diabetic gastroparesis in Belgium (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top